Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
Jake P Mann,
Matthew J. Armstrong,
Hesham K Abdelaziz,
Philip N. Newsome,
Posted 30 Dec 2019
medRxiv DOI: 10.1101/2019.12.24.19015750
Posted 30 Dec 2019
BackgroundNon-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mortality in NAFLD derives from specialist liver centres. We aimed to assess mortality in NAFLD when adjusting for CVD in a real world cohort of inpatients. MethodsRetrospective study of hospitalised patients with 14-years follow-up. NAFL (non-alcoholi c fatty liver), non-alcoholic steatohepatitis (NASH), and NAFLD-cirrhosis groups were defined by ICD-10 codes using ACALM methodology. Cases were age-/sex-matched 1:10 with non-NAFLD hospitalised patients from the ACALM registry. All-cause mortality was compared between groups using cox regression adjusted for CVD and metabolic syndrome risk factors. ResultsWe identified 1238 patients with NAFL, 105 with NASH and 1235 with NAFLD-cirrhosis. There was an increasing burden of cardiovascular disease with progression from NAFL to NASH to cirrhosis. After adjustment for demographics, metabolic syndrome components and cardiovascular disease, patients with NAFL, NASH, and cirrhosis all had increased all-cause mortality (HR 1.3 (CI 1.1-1.5), HR 1.5 (CI 1.0-2.3) and HR 3.5 (CI 3.3-3.9), respectively). Hepatic decompensation (NAFL HR 8.0 (CI 6.1-10.4), NASH HR 6.5 (2.7-15.4) and cirrhosis HR 85.8 (CI 72-104)), and hepatocellular carcinoma were increased in all NAFLD groups. ConclusionThere is a high burden of cardiovascular disease in NAFLD-cirrhosis patients. From a large "real-life" non-specialist registry of hospitalized patients, NAFLD patients have increased overall mortality and rate of liver-related complications compared to controls after adjusting for cardiovascular disease.
- Downloaded 333 times
- Download rankings, all-time:
- Site-wide: 88,531
- In gastroenterology: 87
- Year to date:
- Site-wide: 118,944
- Since beginning of last month:
- Site-wide: 94,102
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!